Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-occurrence of aberrant hepatocyte growth factor (HGF)/MET proto-oncogene receptor tyrosine kinase (MET) and Wnt/β-catenin signaling pathways has been observed in advanced and metastatic prostate cancers.
|
31819003 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of the study were to investigate the relationship between circulating levels of PSA, adipocytokines: omentin, leptin, hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) in serum obtained from patients with benign prostate hyperplasia (BPH) and prostate cancer (PCa).
|
30186533 |
2018 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using a prostate cancer CAF cell line and primary cultures of CAF from prostate cancers, we show that RES activates the N-terminal mutated Transient Receptor Potential Ankyrin 1 (TRPA1) channel leading to an increase in intracellular calcium concentration and the expression and secretion of growth factors (HGF and VEGF) without inducing apoptosis in these cells.
|
28277613 |
2017 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Its role in prostate cancer biology remains poorly understood, therefore the aim of this study was to explore the functional role of endogenously produced RANK in metastatic PC-3 prostate cancer cells in isolation and in response to hepatocyte growth factor (HGF).
|
26977008 |
2016 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.
|
26250899 |
2016 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hepatocyte growth factor and its receptor c-Met are correlated with castration-resistance in prostate cancer.
|
26093299 |
2015 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study aimed to evaluate the effect of HGF on the function of TJs in human prostate epithelial, prostate stem cell-like and prostate cancer cell lines.
|
24858137 |
2014 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a prior study we showed that prostate cancer PC-3 cells exhibit constitutively activated c-Met without exogenous hepatocyte growth factor (HGF); however whether this characteristic is due to an endogenous HGF/c-Met autocrine loop remains controversial.
|
22639908 |
2012 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the role of endogenous TRPC6 channels in the HGF-induced cell proliferation of prostate cancer.
|
20835261 |
2010 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results now show that hepatocyte growth factor synthesized by myofibroblasts associated with prostate cancer cells induces activation of HGF-receptor/cMet and stimulates hyaluronan/CD44v9 signaling.
|
20200161 |
2010 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aberrant expression of HGF/SF and its receptor, c-Met, often correlates with poor prognosis in a variety of human malignancies, including prostate cancer.
|
17283128 |
2007 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that HGF is intimately involved in growth of human prostate cancer and that progression from the androgen-dependent to the androgen-independent state is associated with an adaptive switch in support mechanism from paracrine to autocrine.
|
15277227 |
2004 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
HGF increased both Matrigel invasion and haptotactic migration of prostate cancer cells.
|
12792760 |
2004 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of HGF were investigated on prostate cancer cell line DU145.
|
11948964 |
2002 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we evaluated MET activation by HGF and HGF action in prostate cancer cell lines.
|
10875259 |
2000 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
No variance of tissue content of short variant HGF mRNA encoding a competitive HGF antagonist among the three groups indicated that short variant HGF protein in prostate cancer seemed not to function similarly to a competitive HGF antagonist in benign prostate tissues.
|
9625818 |
1998 |